胃力胶囊联合铝碳酸镁片治疗胆汁反流性胃炎胆胃不和证临床研究  

Clinical Study on Weili Capsules Combined with Hydrotalcite Tablets for Bile Reflux Gastritis with Gallbladder-Stomach Disharmony Syndrome

作　　者：金哲[1] 张静[1] 金建军[1] JIN Zhe;ZHANG Jing;JIN Jianjun

机构地区：[1]河南科技大学临床医学院(河南科技大学第一附属医院),河南洛阳471003

出　　处：《新中医》2023年第10期42-47,共6页New Chinese Medicine

基　　金：河南省医学科技攻关计划项目(201504018)。

摘　　要：目的:观察胃力胶囊联合铝碳酸镁片治疗胆汁反流性胃炎(BRG)胆胃不和证的临床疗效,以及对患者胃肠激素、炎症指标水平的影响。方法:选取150例BRG胆胃不和证患者,按随机数字表法分为对照组和观察组各75例。对照组给予铝碳酸镁片治疗,观察组在对照组基础上给予胃力胶囊治疗,2组均治疗4周。比较2组临床疗效,胆汁反流分级,胃黏膜炎症、第二版慢性胃炎患者生命质量测定量表(QLICD-CG V2.0)、症状评分,以及胃肠激素、炎症指标水平,记录不良反应。结果:治疗后,观察组临床疗效总有效率90.67%,高于对照组76.00%(P<0.05)。2组胆汁反流程度均较治疗前改善(P<0.05),观察组胆汁反流程度比对照组改善更明显(P<0.05)。2组胃黏膜炎症评分均较治疗前降低(P<0.05),QLICD-CG V2.0评分均较治疗前升高(P<0.05);观察组胃黏膜炎症评分低于对照组(P<0.05),QLICD-CG V2.0评分高于对照组(P<0.05)。2组上腹痛、嗳气、胃灼热感、泛酸评分均较治疗前降低(P<0.05),观察组上述4项症状评分均低于对照组(P<0.05)。2组血浆胃动素(MTL)水平均较治疗前升高(P<0.05),血清胃泌素(GAS)、胆囊收缩素(CCK)、肿瘤坏死因子-α(TNF-α)、单核细胞趋化蛋白-1(MCP-1)、白细胞介素-1β(IL-1β)水平均较治疗前降低(P<0.05);观察组血浆MTL水平高于对照组(P<0.05),血清GAS、CCK、TNF-α、MCP-1、IL-1β水平均低于对照组(P<0.05)。治疗期间,2组均未见明显不良反应。结论:胃力胶囊联合铝碳酸镁片治疗BRG胆胃不和证,能安全有效地缓解患者的临床症状,抑制其胆汁反流,减轻内镜下胃黏膜炎症表现,提高患者的生活质量。Objective:To observe the clinical effect of Weili Capsules combined with Hydrotalcite Tablets on bile reflux gastritis(BRG)with gallbladder-stomach disharmony syndrome and its effect on levels of gastrointestinal hormones and inflammatory indexes of patients.Methods:A total of 150 patients with BRG with gallbladder-stomach disharmony syndrome were selected and divided into the control group and the observation group,with 75 cases in each group.The control group was treated with Hydrotalcite Tablets,and the observation group was additionally given Weili Capsules based on the treatment of the control group.Both groups were treated for 4 weeks.The clinical effects,classification of bile reflux,scores of gastric mucosal inflammation,Quality of Life Instruments for Chronic Disease-Chronic Gastritis(QLICD-CG V2.0)and symptoms,and levels of gastrointestinal hormones and inflammatory indexes were compared between the two groups,the adverse reactions were observed.Results:After treatment,the total clinical effective rate was 90.67%in the observation group,higher than that of 76.00%in the control group(P<0.05).The degree of bile reflux in both groups were lessened when compared with those before treatment(P<0.05),and the release of the degree of bile reflux in the observation group was more obvious than that in the control group(P<0.05).The scores of gastric mucosal inflammation in the two groups were decreased when compared with those before treatment(P<0.05),and the QLICD-CG V2.0 scores were increased when compared with those before treatment(P<0.05);the score of gastric mucosal inflammation in the observation group was lower than that in the control group(P<0.05),and the QLICDCG V2.0 score was higher than that in the control group(P<0.05).The scores of abdominal pain,abdominal swelling,nausea and vomiting,and bitter mouth in the two groups were decreased when compared with those before treatment(P<0.05),and the above 4 scores in the observation group were lower than those in the control group(P<0.05).The levels of motil

关 键 词：胆汁反流性胃炎 胆胃不和证 胃力胶囊 铝碳酸镁片 生活质量 胃肠激素 炎症指标 

分 类 号：R573.3[医药卫生—消化系统]